$ENSC
Ensysce Biosciences, Inc. Stock $ensc

$ensc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017430 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$490.5K	$789.6K	$603.1K
YoY Change	136.41%	30.93%	140.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.141M	$1.555M	$2.266M
YoY Change	-41.54%	-31.38%	361.97%
% of Gross Profit
Research & Development	$1.644M	$1.796M	$3.140M
YoY Change	-69.05%	-42.8%	868.03%
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change
% of Gross Profit
Operating Expenses	$2.784M	$3.351M	$5.406M
YoY Change	-61.66%	-38.01%	563.42%
Operating Profit	-$2.294M	-$2.561M	-$4.803M
YoY Change	-67.49%	-46.67%
Interest Expense		$1.497K	-$15.02K
YoY Change		-109.97%
% of Operating Profit
Other Income/Expense, Net	$54.65K	$369.4K	$5.570M
YoY Change	-106.3%	-93.37%
Pretax Income	-$2.239M	-$2.192M	-$950.9K
YoY Change	-71.74%	130.49%	-0.08%
Income Tax
% Of Pretax Income
Net Earnings	-$2.239M	-$2.192M	-$951.1K
YoY Change	-71.74%	130.45%	0.36%
Net Earnings / Revenue	-456.56%	-277.57%	-157.7%
Basic Earnings Per Share	-$0.98	-$2.08	-$14.66
Diluted Earnings Per Share	-$0.98	-$2.08	-$34.86K
COMMON SHARES
Basic Shares Outstanding	1.285M shares	15.43M shares	113.7K shares
Diluted Shares Outstanding	2.274M shares	1.054M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.829M	$1.416M	$8.441M
YoY Change	2.54%	-83.23%	46716.14%
Cash & Equivalents	$3.829M	$1.416M	$8.441M
Short-Term Investments
Other Short-Term Assets	$1.918M	$1.666M	$2.409M
YoY Change	-39.75%	-30.86%	1165.15%
Inventory
Prepaid Expenses	$1.907M	$1.647M
Receivables	$107.6K	$289.3K	$808.6K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.855M	$3.371M	$11.66M
YoY Change	-18.62%	-71.09%	5008.63%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$502.6K	$544.2K	$713.1K
YoY Change	-25.15%	-23.68%	1063.66%
Total Long-Term Assets	$502.6K	$544.2K	$713.1K
YoY Change	-33.37%	-23.68%	-94.41%
TOTAL ASSETS
Total Short-Term Assets	$5.855M	$3.371M	$11.66M
Total Long-Term Assets	$502.6K	$544.2K	$713.1K
Total Assets	$6.358M	$3.915M	$12.37M
YoY Change	-20.02%	-68.36%	-4.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.275M	$1.598M	$959.6K
YoY Change	-58.18%	66.54%	200.65%
Accrued Expenses	$796.8K	$2.378M	$1.769M
YoY Change	-70.28%	34.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$445.7K	$0.00	$6.073M
YoY Change	-82.31%	-100.0%
Total Short-Term Liabilities	$2.517M	$3.976M	$8.802M
YoY Change	-69.48%	-54.83%	2657.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.587M
YoY Change	-100.0%	-100.0%	244.98%
Other Long-Term Liabilities	$47.70K	$91.32K	$871.4K
YoY Change	-86.78%	-89.52%	-91.55%
Total Long-Term Liabilities	$47.70K	$91.32K	$2.458M
YoY Change	-86.78%	-96.29%	-77.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.517M	$3.976M	$8.802M
Total Long-Term Liabilities	$47.70K	$91.32K	$2.458M
Total Liabilities	$2.565M	$4.067M	$10.98M
YoY Change	-70.68%	-62.96%	-0.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$115.4M	-$113.1M
YoY Change	20.84%
Common Stock	$267.00	$128.00
YoY Change	-92.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.119M	$166.7K	$1.391M
YoY Change
Total Liabilities & Shareholders Equity	$6.358M	$3.915M	$12.37M
YoY Change	-20.02%	-68.36%	-4.69%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.239M	-$2.192M	-$951.1K
YoY Change	-71.74%	130.45%	0.36%
Depreciation, Depletion And Amortization			$0.00
YoY Change
Cash From Operating Activities	-$3.109M	-$3.607M	-$3.437M
YoY Change	-30.0%	4.94%	1191.28%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$4.500K
YoY Change		-100.0%	-107.2%
Cash From Investing Activities	$0.00		$4.500K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.522M	$1.875M	-391.3K
YoY Change	-2177.52%	-579.2%	-231.52%
NET CHANGE
Cash From Operating Activities	-3.109M	-$3.607M	-3.437M
Cash From Investing Activities	0.000		4.500K
Cash From Financing Activities	5.522M	$1.875M	-391.3K
Net Change In Cash	2.414M	-$1.732M	-3.824M
YoY Change	-151.29%	-54.71%
FREE CASH FLOW
Cash From Operating Activities	-$3.109M	-$3.607M	-$3.437M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001716947
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2023Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense		usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	ENSC	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023Q1	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1		usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2023Q1	ENSC	Debt Conversion Expens DebtConversionExpens		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	ENSC	Transaction Costs From Public Offering TransactionCostsFromPublicOffering		usd
CY2022Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	ENSC	Stockbased Compensation StockbasedCompensation		usd
CY2022Q1	ENSC	Cash Trueup Liability CashTrueupLiability		usd
CY2022Q1	ENSC	Settlement Of Commitment Fee In Shares SettlementOfCommitmentFeeInShares		usd
CY2023Q1	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees		usd
CY2021Q3	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P3Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	ENSC	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38306
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Ensysce Biosciences, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-2755287
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	7946 Ivanhoe Avenue
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	La Jolla
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92037
CY2023Q1	dei	City Area Code CityAreaCode	(858)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	263-4196
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ENSC
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Bankruptcy Proceedings Reporting Current EntityBankruptcyProceedingsReportingCurrent	true
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1284583	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1415765	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3147702	usd
CY2023Q1	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	289312	usd
CY2022Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	276821	usd
CY2023Q1	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	19015	usd
CY2022Q4	ENSC	Operating Lease Right Of Use Current Asset OperatingLeaseRightOfUseCurrentAsset	27165	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1646553	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1847481	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	3370645	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5299169	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	544217	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	585883	usd
CY2023Q1	us-gaap	Assets Assets	3914862	usd
CY2022Q4	us-gaap	Assets Assets	5885052	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1598166	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2943791	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2358682	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2226494	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	19120	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27315	usd
CY2023Q1	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	4063431	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	4266610	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3975968	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9464210	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	140148	usd
CY2023Q1	ENSC	Liability Classified Warrants Noncurrent LiabilityClassifiedWarrantsNoncurrent	91318	usd
CY2022Q4	ENSC	Liability Classified Warrants Noncurrent LiabilityClassifiedWarrantsNoncurrent	310346	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	91318	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	450494	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4067286	usd
CY2022Q4	us-gaap	Liabilities Liabilities	9914704	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1284664	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	534571	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1284583	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	534490	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	128	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	53	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	113293834	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	107216566	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113127237	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-110931063	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	166725	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-3714444	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-319149	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-315208	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-152424	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3914862	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5885052	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	789635	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	603098	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1796015	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3140096	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1554855	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2265806	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	3350870	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5405902	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2561235	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4802804	usd
CY2023Q1	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-146479	usd
CY2022Q1	ENSC	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-2767178	usd
CY2023Q1	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	219028	usd
CY2022Q1	ENSC	Change In Fair Value Of Liability Classified Warrants ChangeInFairValueOfLiabilityClassifiedWarrants	2794398	usd
CY2022Q1	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1702642	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1497	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	15021	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5419	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	7966	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	369429	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3851879	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2191806	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-950925	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3941	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	182	usd
CY2023Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	8309	usd
CY2022Q1	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	715579	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2196174	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1666686	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-14.66
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1054202	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	113696	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-8158058	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	54250	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	8075343	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2090663	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-950925	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1111273	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4029652	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3056892	usd
CY2023Q1	ENSC	Stock Issued During Period Value Commitment Fee StockIssuedDuringPeriodValueCommitmentFee	400000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2689052	usd
CY2023Q1	ENSC	Transaction Costs Associated With Public Offering TransactionCostsAssociatedWithPublicOffering	-194043	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	117133	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2191806	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-152424	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-152424	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2191806	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-950925	usd
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	4500	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1497	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	15021	usd
CY2023Q1	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-146479	usd
CY2022Q1	ENSC	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	-2767178	usd
CY2023Q1	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	219028	usd
CY2022Q1	ENSC	Change In Fair Value Of Liabilities Classified Warrants ChangeInFairValueOfLiabilitiesClassifiedWarrants	2794398	usd
CY2022Q1	ENSC	Debt Conversion Expens DebtConversionExpens	1702642	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	117133	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	402434	usd
CY2023Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-46	usd
CY2022Q1	us-gaap	Provision For Loan Lease And Other Losses ProvisionForLoanLeaseAndOtherLosses	-46	usd
CY2023Q1	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	12491	usd
CY2022Q1	ENSC	Increase Decrease In Unbilled Receivable IncreaseDecreaseInUnbilledReceivable	366880	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-242594	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-581840	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1345624	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	658526	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-52669	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	86450	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3606919	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3437014	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4500	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4500	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2689052	usd
CY2023Q1	ENSC	Transaction Costs From Public Offering TransactionCostsFromPublicOffering	194043	usd
CY2023Q1	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	415351	usd
CY2023Q1	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	204676	usd
CY2022Q1	ENSC	Repayment Insurance Premiums RepaymentInsurancePremiums	391270	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1874982	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-391270	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1731937	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3823784	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3147702	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12264736	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1415765	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8440952	usd
CY2022Q1	ENSC	Stockbased Compensation StockbasedCompensation	1742479	usd
CY2023Q1	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	3056892	usd
CY2022Q1	ENSC	Conversions Of Convertible Notes Into Common Stock ConversionsOfConvertibleNotesIntoCommonStock	6372701	usd
CY2023Q1	ENSC	Cash Trueup Liability CashTrueupLiability	584857	usd
CY2023Q1	ENSC	Settlement Of Commitment Fee In Shares SettlementOfCommitmentFeeInShares	400000	usd
CY2023Q1	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	8309	usd
CY2022Q1	ENSC	Deemed Dividend Related To Warrants Down Round Provision DeemedDividendRelatedToWarrantsDownRoundProvision	715579	usd
CY2023Q1	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_803_eus-gaap--BasisOfAccounting_zd3g7YxOUPo4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 - <span id="xdx_825_zXaqb0KGjKZ1">BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2023, are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2022, which may be found in the Company’s Form 10-K filed with the SEC on March 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse stock split</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2023, the Company completed a <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20230301__20230331_zPydC3jSwSEa" title="Reverse stock split">1-for-12 reverse split</span> of its outstanding common stock. All references in these consolidated financial statements to shares and per share amounts in all periods have been retroactively restated to reflect the split. The number of authorized shares and the par value of the shares did not change as a result of the reverse stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Going concern</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not generated any product revenue and had an accumulated deficit of $<span id="xdx_90A_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20230331_z501PBfmrI78" title="Accumulated deficit">113.1</span> million at March 31, 2023. There is no assurance that profitable operations will ever be achieved, and, if achieved, could be sustained on a continuing basis. Product development activities, clinical and pre-clinical testing, and commercialization of the Company’s product candidates are necessary to develop the Company’s products and will require significant additional financing. There can be no assurance the Company will be able to obtain such funds. These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $<span id="xdx_909_eus-gaap--CommonStockSharesSubscriptions_iI_pn5n6_c20201231_zbsXTIPZklwg" title="Common stock, subscriptions value">60.0</span> million for a 36-month term following the public listing of the Company’s common stock. The Company controls the timing and maximum amount of drawdown under this facility and has no minimum drawdown obligation. The investor will pay, in cash, a per-share amount equal to 90% of the average daily closing price of the Company’s stock during the 30 consecutive trading days prior to the issuance of a draw notice, which shall not exceed 400% of the average trading volume for the 30 trading days immediately preceding the draw down date. On June 30, 2021, the Company consummated the Business Combination, resulting in the Company’s shares becoming publicly listed on Nasdaq on July 2, 2021. Concurrent with the public listing of the Company’s shares, the Company issued to the investor <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z0LnBHFwGIM" title="Warrants issued shares">4,608</span> warrants with a five-year term to purchase common stock of Ensysce at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pp2d_c20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zdTog07v9Tgj" title="Warrant, exercise price">2,402.40</span> per share (Note 8). The Company was required to pay a commitment fee to the investor of $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zVn5XUxLa4x4" title="Commitment fees">1.2</span> million with $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--FirstAnniversaryMember_z8jbC8tSWQF8" title="Commitment fees">0.8</span> million due on the first anniversary of the public listing date and $<span id="xdx_90C_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20210601__20210630__srt--TitleOfIndividualAxis__us-gaap--InvestorMember__us-gaap--AwardDateAxis__custom--EighteenMonthAnniversaryMember_zKDfPxpaWLG9" title="Commitment fees">0.4</span> million due on the 18-month anniversary of the public listing date. The first $<span id="xdx_908_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JulyTwentyTwentyTwoMember_zYNvojx92lO4" title="Commitment fees">0.8</span> million of the commitment fee was paid in July 2022 in common stock of the Company (Note 10) and the remaining $<span id="xdx_90B_eus-gaap--DebtRelatedCommitmentFeesAndDebtIssuanceCosts_pn5n6_c20220701__20220731__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--AwardDateAxis__custom--JanuaryTwentyTwentyThreeMember_z57DHG2vD6K3" title="Commitment fees">0.4</span> million was paid in January 2023 in common stock of the Company. Usage of the GEM facility is limited by other agreements of the Company. The Company has not raised any capital to date pursuant to the GEM facility and may not raise any capital pursuant to it prior to its expiration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-12 reverse split
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113100000	usd
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	60000000.0	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zsxQ51zvQg17" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zqId2hNHkx7e">Use of estimates and assumptions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_z0RkaQVI2J95" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_z6Mzw8lrst37">Concentrations of credit risk and off-balance sheet risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
CY2023Q1	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	91318	usd
CY2023Q1	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	91318	usd
CY2022Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	4203579	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	310346	usd
CY2022Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	4513925	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	4513925	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-3056892	usd
CY2023Q1	ENSC	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Cash Payments FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCashPayments	-415351	usd
CY2023Q1	ENSC	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Cash Trueup Liability FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityCashTrueupLiability	-584857	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-365507	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	91318	usd
CY2018Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5100000	usd
CY2022Q2	us-gaap	Grants Receivable GrantsReceivable	10700000	usd
CY2019Q3	us-gaap	Grants Receivable GrantsReceivable	5400000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	789635	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	603098	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	789635	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	603098	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	885654	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	119214	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	885654	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	119214	shares
CY2023Q1	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	393077	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	421530	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	672257	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	72251	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2358682	usd
CY2023Q1	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	1180547	usd
CY2022Q4	ENSC	Prepaid Research And Development PrepaidResearchAndDevelopment	1300473	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	314990	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	445583	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	151016	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	101425	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1646553	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1847481	usd
CY2023Q1	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	1293348	usd
CY2022Q4	ENSC	Accrued Research And Development AccruedResearchAndDevelopment	1332713	usd
CY2022Q4	ENSC	Share Subscription Facility Commitments Fees ShareSubscriptionFacilityCommitmentsFees	400000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2226494	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	20400000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	19120	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	8375	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	7834	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	0	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	4100537	usd
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	18450	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	287771	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	4406758	usd
CY2023Q1	ENSC	Stated Interest Accrual StatedInterestAccrual	1497	usd
CY2022Q1	ENSC	Stated Interest Accrual StatedInterestAccrual	2004	usd
CY2023Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	1497	usd
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	2004	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.08	pure
CY2023Q1	us-gaap	Notes Payable NotesPayable	600000	usd
CY2022	ENSC	Financed Insurance Premiums FinancedInsurancePremiums	399949	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Dividends Payable Amount Per Share DividendsPayableAmountPerShare	0.001
CY2021Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	78751	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	296845	usd
CY2023Q1	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Weighted Average Period Expected To Be Recognized SharebasedCompensationArrangementBySharebasedPaymentAwardWeightedAveragePeriodExpectedToBeRecognized	P1Y5M23D
CY2022Q4	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	7782	shares
CY2021Q2	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-06-30
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4608	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.58
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1504	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3008	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1831.20
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1831.20
CY2021Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-09-23
CY2021Q4	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2026-09-23
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	19447	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	19447	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	170.04
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	170.04
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-06-29
CY2022Q3	us-gaap	Warrants And Rights Outstanding Maturity Date WarrantsAndRightsOutstandingMaturityDate	2027-08-08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26334	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	707.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M10D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	26334	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	707.63
CY2023Q1	ENSC	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P6Y3M14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	23922	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	729.16
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	26334	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	707.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y3M14D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7612	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9587	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0152	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0220	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.01
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1045740	shares
CY2022Q4	us-gaap	Share Price SharePrice	16.80
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	550000	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3838	shares

Files In Submission

Name	View Source	Status
ensc-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ensc-20230331_lab.xml	Edgar Link	unprocessable
ensc-20230331_pre.xml	Edgar Link	unprocessable
0001493152-23-017430-index-headers.html	Edgar Link	pending
0001493152-23-017430-index.html	Edgar Link	pending
0001493152-23-017430.txt	Edgar Link	pending
0001493152-23-017430-xbrl.zip	Edgar Link	pending
ensc-20230331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ensc-20230331_def.xml	Edgar Link	unprocessable
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENSC
Ensysce Biosciences, Inc. Stock $ensc

2023 Q2 Form 10-Q Financial Statement

#000149315223017430 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC Ensysce Biosciences, Inc. Stock $ensc

2023 Q2 Form 10-Q Financial Statement

#000149315223017430 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENSC
Ensysce Biosciences, Inc. Stock $ensc